Liquid biopsy
2 blood samples
Scroll down to discover
OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample for all advanced cancer patients.
When patients cannot have their tumor biopsied, when their tumor tissue sample is too old or too scarce for comprehensive biomarker testing, OncoSELECT is the perfect alternative to help in treatment strategies optimization and to support clinical decisions. It can be used as a tool to detect treatment resistance to targeted therapies and hormone therapies (before first line to assess the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations or to inform on the patient's response to chemotherapy in neoadjuvant settings) as well as determine patient potential eligibility to clinical trials.
Liquid biopsy
2 blood samples (2x10ml Streck tubes)
OncoSELECT detects potential sensitivity or resistance to targeted therapies and hormone treatments by targeting 58 genes associated with treatment response (SNVs, indels, translocations and TERT promoter).
It is recommended for patients whose tissue sample is not available or is limited, when it is challenging or not possible to perform a solid biopsy, or if the tumor tissue sample is too old.
OncoDNA scientific team regularly publishes studies in peer-reviewed international journals. We have selected for you the key scientific publications that highlight the clinical impact of our biomarker tests.
Male, 55 years old
Oncologists requested to perform a liquid biopsy test since the lung needle biopsy obtained was of limited quantity. The patient was progressing under erlotinib. OncoSELECT allowed the detection of EGFR T790M variant. The detection of this variant led the oncologist to choose osimertinib which resulted in good response without any known relapse so far.
Female, 43 years old, under tamoxifen
OncoSELECT was chosen performed because no solid biopsy was available for this patient. It allowed the identification of ESR1 L536Q and PIK3CA E545K variants in this patient who has been receiving tamoxifen for 5 years. Based on the presence of these biomarkers, it was decided to prescribe a combination of alpelisib and fulvestrant.
Male, 63 years old, under cabozantinib
OncoSELECT enabled the identification of an AR V890M variant that has been reported in patients affected with androgen insensitivity. This variant explains the lack of clinical benefit from hormone therapies previously administered to the patient (AR inhibitors abiraterone and enzalutamide) and from cabozantinib. Moreover, the detection of pathogenic BRCA2 variant and deleterious homologous recombination repair gene ATM R3008C variant led to the prescription of the FDA-approved PARP inhibitor olaparib.
OncoDEEP® offers a unique combination of DNA, RNA and protein biomarker tests on solid biopsies. In less than two weeks, OncoDEEP is able to pinpoint the therapeutic vulnerabilities of an advanced, metastatic tumor and to recommend appropriate treatment options. The test screens for genomic alterations (DNA & RNA), genomic signatures (MSI, TMB, HRD) and protein biomarkers of response to targeted therapies, immunotherapies, hormone therapy and chemotherapy.
OncoFOLLOW is a test based on the analysis of circulating tumor DNA in blood. It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears.
This assay is customised for each patient, as it analyses variants previously identified in the tumour of the patient.
In 2013, OncoDNA became the first company to launch a personalised liquid biopsy test.
Ordering a solution is very simple: Just log in to OncoSHARE and select the solution(s) you are interested in. If you do not have a kit for sample collection, we will send you one.
After sample processing and interpretation by our expert team, a comprehensive report will be available for you on OncoSHARE. In a simple and interactive manner, it will help you with the selection of the most appropriate treatments based on the unique signature of your patient's tumour. Moreover, you will be able to share the report with your colleagues.
For information regarding the price of our OncoSELECT biomarker test in your respective country, please contact our sales team.
Cannot find what you are looking for? Contact us! Our Scientific Support Teams are available to answer all your questions from Monday to Friday.
